24
Sep
Fireside chat: From niche to Nasdaq - EQL Pharma's journey to the Main Market
Join Adam Kostyál, President of Nasdaq Stockholm, and Axel Schörling, CEO of EQL Pharma, as they discuss EQL Pharma's recent listing on the Nasdaq Stockholm Main Market. This insightful conversation will explore the company's rapid growth, the impact of the listing and the future of pharmaceuticals in the Nordic region.
- What was the rationale behind EQL Pharma’s decision to focus on niche generics and cost-efficient medicines and how does this strategy position EQL Pharma in the competitive pharmaceutical landscape?
- What did the process of moving to Nasdaq Stockholm’s Main Market involve? And what were they key factors in driving this decision? How does it align with EQL Pharma’s growth objectives?
- What role does Nasdaq’s Main Market play in EQL Pharma’s ambitious growth plans and how does this intersect with boarder trends in the Nordic pharmaceutical industry? What role do capital markets play in supporting innovation and expansion in the sector?
Join Adam Kostyál, President of Nasdaq Stockholm, and Axel Schörling, CEO of EQL Pharma, as they discuss EQL Pharma's recent listing on the Nasdaq Stockholm Main Market. This insightful conversation will explore the company's rapid growth, the impact of the listing and the future of pharmaceuticals in the Nordic region.
- What was the rationale behind EQL Pharma’s decision to focus on niche generics and cost-efficient medicines and how does this strategy position EQL Pharma in the competitive pharmaceutical landscape?
- What did the process of moving to Nasdaq Stockholm’s Main Market involve? And what were they key factors in driving this decision? How does it align with EQL Pharma’s growth objectives?
- What role does Nasdaq’s Main Market play in EQL Pharma’s ambitious growth plans and how does this intersect with boarder trends in the Nordic pharmaceutical industry? What role do capital markets play in supporting innovation and expansion in the sector?
-
SpeakersAdam Kostyál President Nasdaq Stockholm & Head of European Listings & Capital Markets NASDAQ
Axel Schörling CEO EQL PHARMA
Anette Jönsson Senior Editor DEALREPORTER & MERGERMARKET
Confirm cancellation
Something went wrong.
An error occurred trying to play the stream. Please reload the page and try again.
CloseSign-up to join the ION Analytics Community to:
- Register for events
- Access market insights
- Download reports
Adam Kostyál has been with Nasdaq for the more than 20 years. He currently is the President of Nasdaq Stockholm and also manages the Listing franchise for Nasdaq in Europe. This includes the Nasdaq Stockholm, Nasdaq Copenhagen, and Nasdaq Helsinki listing offering. In addition he also manages the listing offering for Nordic companies wanting to list or dual list in the US. Prior to his current role Adam held various positions within Nasdaq and prior to this with Cell Network, Bloomberg and Enron. He holds a B.A in Economics and Marketing from Vrije Universiteit, Bruxelles, and speaks four languages including English, Swedish, Italian and French, and is also the proud father of five children!
Axel Schörling has a background in Consulting and Finance. Overall, he has extensive experience from various industries and assignments in Supply chain, Operations and Finance. Axel has been with EQL Pharma since 2018 when he joined as COO, in 2020 he was promoted to Deputy-CEO and in 2022 to CEO. The revenue of EQL has gone from about 25 MSEK to about 300 MSEK and the market cap from about 290 MSEK to about 1600 MSEK during Axel´s time with the firm. Axel holds a M.Sc. in Engineering Physics from Chalmers and a M.Sc. in Financial Economics from Gothenburg School of Economics. Axel is the 3rd largest physical shareholder in EQL and the 9thlargest shareholder, also considering institutions.
A Swedish national, Anette moved to London last year after spending 23 years in Hong Hong, covering corporate news, ECM and M&A. Before leaving Asia she was editor of Dealreporter APAC, focusing on event-driven and special situations. Previous employers include FinanceAsia (where she covered ECM primarily for the website), South China Morning Post and Dow Jones Newswires.
In her current London-based role, she primarily edits stories on public and private market M&A as well as regulatory content.